APC Anti-Annexin A1/ANXA1 antibody [EPR19342],Abcam,AB225511

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Mouse, Human, Mouse, Rat

Application

ICC/IF, IHC-P, Flow Cyt (Intra)

Conjugate

APC

Platform ID

BAB454771014

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAPC Anti-Annexin A1/ANXA1 antibody [EPR19342]
Cat. No.AB225511
HostRabbit
IsotypeIgG
ReactivityMouse, Human, Mouse, Rat
ConjugationAPC
ApplicationICC/IF, IHC-P, Flow Cyt (Intra)
ClonalityMonoclonal
Clone NumberEPR19342
Concentration0.5 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 1% BSA
Storage+4°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Plays important roles in the innate immune response as effector of glucocorticoid-mediated responses and regulator of the inflammatory process. Has anti-inflammatory activity (PubMed : 8425544). Plays a role in glucocorticoid-mediated down-regulation of the early phase of the inflammatory response (By similarity). Contributes to the adaptive immune response by enhancing signaling cascades that are triggered by T-cell activation, regulates differentiation and proliferation of activated T cells (PubMed : 17008549). Promotes the differentiation of T cells into Th1 cells and negatively regulates differentiation into Th2 cells (PubMed : 17008549). Has no effect on unstimulated T cells (PubMed : 17008549). Negatively regulates hormone exocytosis via activation of the formyl peptide receptors and reorganization of the actin cytoskeleton (PubMed : 19625660). Has high affinity for Ca(2+) and can bind up to eight Ca(2+) ions (By similarity). Displays Ca(2+)-dependent binding to phospholipid membranes (PubMed : 2532504, PubMed : 8557678). Plays a role in the formation of phagocytic cups and phagosomes. Plays a role in phagocytosis by mediating the Ca(2+)-dependent interaction between phagosomes and the actin cytoskeleton (By similarity). In the context of antitumor immunity, interacts with FPR1 on dendritic cells allowing for tumor-associated antigens uptake and cross-presentation to T cells to mount an antitumor specific T cell response.. Annexin Ac2-26. Functions at least in part by activating the formyl peptide receptors and downstream signaling cascades (PubMed : 15187149, PubMed : 22879591, PubMed : 25664854). Promotes chemotaxis of granulocytes and monocytes via activation of the formyl peptide receptors (PubMed : 15187149). Promotes rearrangement of the actin cytoskeleton, cell polarization and cell migration (PubMed : 15187149). Promotes resolution of inflammation and wound healing (PubMed : 25664854). Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 (PubMed : 22879591). See full target information ANXA1

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.